Charles River Laboratories beats earnings estimates by $0.13 in Q3

Trending News 🌥️

CRL Intrinsic Stock Value – Charles River Laboratories ($NYSE:CRL) is a global provider of biologic and preclinical contract research services to the pharmaceutical and biotechnology industries. The company reported its third quarter results today, with Non-GAAP EPS of $2.63 beating analysts’ estimates by $0.13. Charles River Laboratories has a long history of providing high-quality services to its clients, and this quarter’s results are a testament to that. The company has a diversified business model that is able to withstand economic headwinds, and this has served it well in the current environment.

Looking forward, Charles River Laboratories is well-positioned to continue its growth trajectory. The company is investing in new capabilities and expanding its global footprint. This will allow it to serve its clients even better and continue to generate strong results.

Earnings

Charles River Laboratories International, Inc. today announced that it has earned $0.13 per share in its third quarter of fiscal year 2022, beating analysts’ estimates by $0.13. In its earning report of FY2022 Q2 ending June 30, CHARLES RIVER LABORATORIES INTERNATIONAL earned 3688.0M USD in total revenue, earned 443.3M USD in net income. Compared to previous year, 4.2% increase in total revenue, 13.4% increase in net income. CHARLES RIVER LABORATORIES INTERNATIONAL’s total revenue reached from 2923.9M USD to 3688.0M USD in the last 3 years.

The company’s strong performance was driven by its continued focus on execution and disciplined cost management. Charles River Laboratories is a leading provider of essential products and services to help pharmaceutical and biotechnology companies accelerate their research and development. The company’s focus on quality and customer service has enabled it to win repeat business from its clients.

Price History

Charles River Laboratories stock surged 4.1% Wednesday after the company reported better-than-expected earnings for the third quarter. Charles River Laboratories attributed the strong results to continued growth in its core lab services business, as well as higher demand for its preclinical and discovery services. Despite the strong results, shares of Charles River Laboratories ended the day modestly lower as investors took profits after the stock’s recent run-up.

VI Analysis – CRL Intrinsic Stock Value

Charles River Laboratories International is a provider of products and services for the pharmaceutical and biotechnology industries. The company’s products and services include preclinical and clinical research services, as well as manufacturing and support services. CRL has a long history of providing products and services that are essential to the development and commercialization of new therapies. The company’s fundamentals reflect its long-term potential.

CRL’s products and services are essential to the development and commercialization of new therapies, and the company has a strong track record of delivering high-quality products and services. CRL’s intrinsic value is around $291.1 per share, calculated by VI Line. The company’s stock is currently traded at $215.8, meaning it is undervalued by 26%.

VI Peers

The global market for contract research services is growing rapidly as more and more companies are outsourcing their research and development needs. This growth is being driven by the increasing costs of R&D, the need for faster timelines, and the desire to tap into the expertise of experienced professionals. As the market expands, so does the competition, and Charles River Laboratories International Inc is up against some stiff competition from the likes of Microba Life Sciences Ltd, IDenta Corp, and Eurofins Scientific SE.

– Microba Life Sciences Ltd ($ASX:MAP)

Denta Corp is a publicly traded company that provides dental products and services. The company has a market capitalization of 1.5 million as of 2022 and a return on equity of -10.42%. The company’s products and services include dental implants, dentures, and other dental prosthetics. Denta Corp also provides dental education and training services. The company was founded in 2006 and is headquartered in New York, New York.

– IDenta Corp ($OTCPK:IDTA)

Eurofins Scientific SE is a global leader in the provision of analytical testing and scientific services. The company has a market capitalization of 13.54 billion as of 2022 and a return on equity of 12.32%. The company provides a range of services including food testing, environmental testing, pharmaceutical testing, and forensics. Eurofins Scientific SE has a network of over 800 laboratories across 47 countries.

Summary

If you’re looking for a stock that’s beaten earnings estimates in the past and is likely to do so again in the future, Charles River Laboratories International is a good option. The company’s stock price has tended to move up on the day it reports earnings, so investors who buy before earnings are released and hold through the announcement may be able to make a profit. CRL is a leading provider of research services and products to the pharmaceutical and biotechnology industries. The company has a long history of delivering high-quality services and products that help its customers speed up the drug development process.

Investors who are bullish on the pharmaceutical industry may want to consider buying CRL stock. The company is well-positioned to benefit from the continued growth of the industry.